Rapport Therapeutics (RAPP) announced plans to initiate its Phase 3 program for RAP-219 in FOS in the second quarter of 2026 and expand its epilepsy portfolio with a new program in PGTCS. Additionally, the Company announced progress across its pipeline, including its Phase 2 bipolar mania trial, long-acting injectable development, FDA’s removal of the clinical hold on its Phase 2 diabetic peripheral neuropathic pain trial, and advancement of additional pipeline programs.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Rapport Therapeutics price target raised to $40 from $34 at H.C. Wainwright
- Promising Outlook for Rapport Therapeutics: Buy Rating Backed by RAP-219’s Clinical Success and Strategic Growth Plans
- Rapport Therapeutics announces new data, post hox analysis on RAP-219
- Buy Rating for Rapport Therapeutics: Promising Efficacy and Market Potential of RAP-219 in Epilepsy and Bipolar Mania
- Rapport Therapeutics initiated with a Buy at BTIG